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ABSTRACT 
The impact of patient/donor matching for HLA-A, -B, -C, -DRB1 and -DQB1 genes in 
hematopoietic stem cell transplantation (HSCT) is well-recognized, but typing for additional 
genes, such as HLA-DPB1, is still controversial. Based on defined T-cell epitope (TCE) 
groups, all HLA-DPB1 mismatches can be classified as permissive or non-permissive. In this 
retrospective study we analysed 82 patient/matched unrelated donor (MUD) pairs who 
underwent HSCT, and explored the impact of HLA-DPB1 matches, permissive and non-
permissive mismatches on transplantation outcomes. Patient/MUD pairs matched for HLA-
DPB1 alleles in univariate analysis were associated with a significantly higher incidence of 
disease relapse compared to pairs who were permissive/non-permissive HLA-DPB1 
mismatched according to the TCE3 and TCE4 algorithms (P = 0.025 and P = 0.026, 
respectively), although the significance was lost in multivariate analysis. The analysis did not 
reveal any significant influence of HLA-DPB1 alleles on overall survival (OS), non-relapse 
mortality (NRM) or graft-versus-host disease (GVHD) incidence. In conclusion, our study 
presents evidence that HLA-DPB1 matching influenced the relapse rate in patients after 
HSCT so the HLA-DPB1 alleles should be implemented in the MUD search algorithm as a 
transplantation determinant. 
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Introduction 
The huge polymorphism of the classical human leukocyte antigen (HLA) genes and 
the recognition of HLA incompatibilities by the immune system represent a major barrier to 
allogeneic hematopoietic stem cell transplantation (HSCT) [1]. To lower risks of acute graft-
versus-host disease (GVHD) and mortality after HSCT, high resolution typing and matching 
for HLA-A, -B, -C, -DRB1, and -DQB1 alleles (10/10 match) between unrelated donor and 
patient still remains the gold standard, while the importance of HLA-DPB1 gene remains 
uncertain and pre-transplantation typing is not routinely performed. Because of weak linkage 
disequilibrium between HLA-DPB1 alleles and other HLA class II alleles [2], HSCT is 
generally performed across HLA-DPB1 allelic mismatches. 
The HLA-DBP1 gene is located in the HLA class II region of the chromosome 6p21.3, 
lying centromeric to the other HLA class II loci. It is highly polymorphic and in the terms of 
structure and function HLA-DPB1 resembles other HLA class II molecules - they are cell-
surface heterodimers, consisting of an alpha and beta chain, that function as receptors for 
processed peptides derived predominantly from membrane and extracellular proteins, which 
they present to CD4 T lymphocytes initiating an immune response [3]. The common 
assumption is that HLA-DP molecules are less important in the immune response than HLA-
DR or HLA-DQ molecules, because of a ~10-fold lower cell surface expression [4]. However, 
the HLA-DPB1 gene encodes fully functional molecules with specific responses reported in a 
number of settings. 
 In the performed in vitro assays set up to detect anti-HLA-DP alloreactive T cells, the 
observed T-cell reactivity patterns suggest the expression of a shared T-cell epitope (TCE) 
encoded by the HLA-DPB1 alleles [5]. The HLA-DPB1 alleles were thus classified according 
to their predicted immunogenicity in to high immunogenic group 1 (HLA-DPB1*09:01, 
*10:01, *17:01), intermediately immunogenic group 2 (HLA-DPB1 *03:01, *14:01, *45:01), 
and poorly immunogenic group 3 (most other HLA-DPB1 alleles). On the basis of a shared 
alloreactive T-cell epitope, the TCE3 algorithm was proposed for use in unrelated donor 
selection identifying permissive or non-permissive HLA-DPB1 mismatches. Later, a modified 
4-group algorithm (TCE4), including the HLA-DPB1*02 gene as a separate group with 
immunogenicity lower than that of group 2 alleles but higher than that of the low 
immunogenic alleles in group 3, was designed [6]. The latest classification into three TCE 
immunogenic groups, including 390 HLA-DPB1 alleles, was reported by Crivello et al. [7]. 
 
To date, the biological role of HLA-DP in HSCT still remains controversial. 
Retrospective studies analysing HLA-DPB1- matching status between matched unrelated 
donors (MUDs) and recipients at the allelic level, or classified as permissive/non-permissive 
mismatches were performed [5, 6, 8-19]. The given results are heterogeneous and an 
overview of results from literature is summarized in Table 1. However, analysis suggests that 
HLA-DPB1 classification according to T-cell epitope grouping can identify permissive and 
non-permissive unrelated recipient-donor combinations relevant to GVHD occurrence, 
mortality and disease relapse rate after HSCT. 
In an effort to contribute to the clarification of the role of HLA-DPB1 in HSCT, we 
performed a retrospective single centre analysis of the impact of permissive/non-permissive 
HLA-DPB1 disparities on the overall survival (OS), non-relapse mortality (NRM), GvHD 
occurrence and disease relapse rate among 82 patients who underwent HSCT from MUD. The 
validation of these findings could support the utility of including HLA-DPB1 alleles in pre-
transplantation typing to further improve MUD selection. 
 
 
 
2. Materials and methods 
2.1. Study population 
The study included 82 patients with hematological malignancies who had received a 
hematopoietic stem cell transplant from a 10/10 (HLA-A, -B, -C, -DRB1, -DQB1) MUD in 
the period of 2010 – 2015 at the University Hospital Centre Zagreb, Department for Internal 
Medicine, Division of Hematology. Namely, the University Hospital Centre Zagreb is the 
only hospital in Croatia where unrelated HSCT is performed and the patients originated from 
different areas of Croatia. The included patients were adults (N=67) or children (N=15) with a 
broad range of diseases that were an indication for HSCT: acute myelogenous leukaemia 
(AML, N=37),  acute lymphoblastic leukaemia (ALL, N=17), myelodysplastic syndrome 
(MDS, N=6), chronic myelogenous leukaemia (CML, N=3), non-Hodgkin lymphoma (NHL, 
N=4), Hodgkin lymphoma (HL, N=3), myelofibrosis (MF, N=2), severe combined 
immunodeficiency (SCID, N=3) and other malignancies (N=7). The majority of the patients 
were treated with a reduced-intensity conditioning (RIC) regimen mainly based on 
fludarabine in a dose of 30 mg/m2 daily over 4-6 days, IV busulfan 3.2 mg/kg daily over 2-3 
days, and anti–thymocyte globulin (ATG) in a total dose of 5 mg/kg infused over 2 days. 
Other patients were treated with a myeloablative conditioning regime (MAC) receiving IV 
busulfan in a daily dose of 3.2 mg/kg over 4 days, 60 mg/kg of cyclophosphamide over 2 days 
and ATG in total dose of 1.5 mg/kg over 11 hours. GvHD prophylaxis was performed with 
cyclosporine (CsA) and mycophenolate mofetil (MMF). Patients received bone marrow (BM) 
grafts or peripheral blood stem cell (PBSC) grafts, mobilized from donors with granulocyte-
colony-stimulating factor (GCSF) (filgrastime, 10 μg/kg per day). No manipulation of the 
graft, such as T-cell depletion, was performed in any of the cases. Characteristics of the 
patients and their MUDs are given in Table 2. 
 
2.2. HLA typing  
All patient-MUD pairs were HLA typed at the allelic level for HLA-A, -B, -C, -DRB1 
and -DQB1 using the standard polymerase chain reaction-sequence specific priming (PCR-
SSP) protocol for Olerup SSP® typing kits (Olerup GmbH, Vienna, Austria) or by PCR-
sequence specific oligonucleotide probing (PCR-SSOP) method, using the commercially 
available Immucor Lifecodes HLA-SSO typing kit (Immucor Transplant Diagnostics, Inc, 
Stamford, USA) [20, 21]. For the purpose of this study, the retrograde allelic HLA-DPB1 
typing of patients and their MUDs was performed using the Luminex technology (Immucor) 
in the combination with PCR-SSP method (Olerup). The combination of alleles that could not 
be discriminated (HLA-DPB1*03:01/104:01 and DPB1*04:02/105:01) was designated by 
case ‘P’ and the common alleles were used for alternative genotypes. 
 
2.3. Study design 
The first step was to determine whether the patient and their MUD were HLA-DPB1- 
matched or mismatched (MM) and HLA-DPB1 alleles were assigned to corresponding 
immunogenic T-cell-epitope groups (group 1, 2, 3 and/or 4). Furthermore, all patient-MUD 
pairs (N=75) who were a single or a double HLA-DPB1 allele MM were classified as 
permissive (T-cell-epitope group matched) or non-permissive (T-cell-epitope group MM) 
according to TCE3 [5, 7] and TCE4 [6] algorithm. The patient-MUD pairs were defined as 
HLA-DPB1 permissive mismatched if both the patient's and the donor's HLA-DPB1 alleles 
were from the same immunogenic group (1/1, 2/2, 3/3 and/or 4/4) or they carried at least one 
allele from the high immunogenic group 1 (1/2, 1/3 and/or 1/4). Also, pairs were permissive 
mismatched if neither the patient nor donor had a group 1 allele but carried at least one 
immunogenic group 2 allele (2/3 and/or 2/4). Additionally, in TCE4 classification a part of 
the TCE3-permissive disparities (3/3) becomes non-permissive, and only patient-MUD pairs, 
both carrying at least one immunogenic group 3 allele (3/4 vs 4/4), were permissive 
mismatched. All non-permissive TCE3 disparities were also TCE4 non-permissive. For 
confirmation, the classification of all patient-MUD pairs was also performed using an online 
calculator, the DPB1 T-Cell Epitope Algorithm v2.0 (http://www.ebi.ac.uk). Patient-MUD 
pairs without HLA-DPB1 allelic MMs (N=7) were not included in permissive HLA-DPB1 
disparity. Since the chance of matching for HLA-DPB1 was the same whether the other HLA 
loci were matched or not [10], we analysed HLA-DPB1 matching as an individual risk factor 
for transplantation outcomes. Clinical data were collected from the transplantation centre and 
the effect of HLA-DPB1 match and HLA-DPB1 permissive/non-permissive MMs on HSCT 
outcome were estimated. The OS, NRM, GvHD incidence and disease relapse rate were the 
main research endpoints analysed. The starting point for time-to-event analysis was “date of 
transplantation”. The OS rate was defined as the time to death from any cause. Surviving 
patients were censored at the time of last follow-up. NRM was defined as all causes of death 
without evidence of initial disease. Acute and chronic GvHD were diagnosed according to the 
standard criteria [22, 23]. 
 
2.4. Statistical analysis 
The observed HLA-DPB1 allele frequencies in the research group were calculated by 
direct counting. The 2-year probabilities of OS were analysed using Kaplan-Meier methods 
evaluating the influence of the HLA-DPB1 matches/mismatches on specified transplantation 
endpoint. Cumulative incidence was used to estimate the disease relapse rate, NRM and 
probability of GvHD occurrence after HSCT. Death without relapse was regarded as a 
competing risk for relapse, and relapse as a competing risk for non-relapse mortality. The 
two-sided P values were obtained from the log-rank test and were set to P≤ 0.05. Logistic 
regression analysis was performed to explore the effect of major clinical variables (patient age 
at transplantation, patient/MUD gender, source of stem cells, conditioning regimen) with 
HSCT outcome. The likelihood ratio and significance values are presented as Odds Ratio 
(OR) with a 95% Confidence Interval (CI) and the P-value for each variable. All statistical 
analyses were performed using XLSTAT-Biomed solution software, version 2017.3. 
 
3. Results  
3.1. HLA-DPB1 allele polymorphism  
Among the 82 patient-MUD pairs in this study, only 22 of the 894 HLA-DPB1 alleles 
known to date (IMGT/HLA database v.3.29) [24] were detected. The most frequent HLA-
DPB1 alleles were HLA-DPB1*04:01 (37.19%), followed by DPB1*04:02P (17.68%), 
DPB1*02:01 (12.19%), DPB1*03:01P (9.14%) and DPB1*01:01 (6.09%). The remaining 17 
alleles had a frequency of less than 5.0%. In the patient group, 60 (73.17%) samples were 
HLA-DPB1 heterozygous and 22 (26.83%) samples were homozygous. A similar distribution 
of HLA-DPB1 heterozigosity (59/82) and homozigosity (23/82) was detected among the 
MUDs. 
 
3.2. HLA-DPB1 matching status of patients and their MUDs 
Out of the 82 patient-MUD pairs studied, only 7 pairs shared a complete identity for 
all 12 HLA alleles (12/12). Consequently, the rate of HLA-DPB1 allele match between 
patients and MUDs is 8.53%. The remaining 75 pairs had at least one (50/75) or both (25/75) 
allelic MM at HLA-DPB1. According to the TCE3 algorithm, permissive MMs were present 
in 38 (50.66%) patient-MUD pairs and non-permissive HLA-DPB1 MMs were detected in 37 
(49.34%) pairs (12 HvG; 25 GvH direction). While considering HLA-DPB1*02 as a separate 
immunogenic group according to the TCE4 algorithm, 24 (32.0%) patient-MUD pairs were 
permissive mismatched, while non-permissive HLA-DPB1 MMs were detected in 51 (68.0%) 
pairs (18 HvG; 33 GvH direction). 
 
3.3. Clinical outcome 
Overall survival. The estimated 2-year probability of OS in the whole group was 
53.65%. There was no significant difference in OS between those recipient-MUD pairs who 
were matched and those who were (TCE3 and TCE4) permissive/non-permissive mismatched 
for HLA-DPB1 alleles, (TCE3: OR = 0.58 [CI, 0.32–7.72], P = 0.41; TCE4: OR = 3.42 [CI, 
0.61–19.39], P = 0.58), although there is the tendency of worse OS for HLA-DPB1-matched 
recipient-MUD pairs (Figure 1a and 2a). Logistic regression analysis showed that none of the 
analysed baseline characteristics regarding age, gender, conditioning regime, source of stem 
cells and HLA compatibility have a significant influence on OS (Table 3). 
Non-relapse mortality. The 2-year probability of NRM was 26.83%. According to the 
univariate analysis the impact of HLA-DPB1 matched and TCE3 or TCE4 permissive/non-
permissive HLA-DPB1 mismatched recipient-MUD pairs had no deleterious impact on NRM 
(TCE3: OR = 0.30 [CI, 0.03–2.65], P = 0.91; TCE4: OR = 1.22 [CI, 0.11–13.97], P = 0.82) 
(Figure 1b and 2b). The only factor showing a statistically significant (P=0.04) influence on 
NRM in logistic regression analysis were the patient’s age <18 (Table 3) while other factors 
were not significantly associated.  
Graft versus host disease. The overall incidence of GvHD was 37.81%. Among 31 
GvHD positive patients, 23 were determined as having acute GvHD while 8 patients revealed 
chronic GvHD. The univariate analysis of clinical data from the HLA-DPB1-matched and the 
HLA-DPB1 (TCE3 and TCE4) permissive/non-permissive mismatched groups revealed no 
significant difference of GvHD incidence (TCE3: OR = 0.55 [CI, 0.09–3.12], P = 0.54; TCE4: 
OR = 0.85 [CI, 0.13–5.36], P = 0.90) (Figure 1c and 2c). Patient, donor and graft variables 
were not significantly associated with GvHD occurrence in logistic regression analysis (Table 
3) 
 Relapse. Among our group of analysed patients, 19 relapsed. The HLA-DPB1 allele 
matched recipient-MUD pairs were associated with significant increase in disease relapse 
compared with both permissive and non-permissive HLA-DPB1 allele MMs, according to 
both the TCE3 (OR = 4.72 [CI, 0.91–24.36], P = 0.025) and the TCE4 (OR = 7.02 [CI, 1.12–
44.01], P = 0.026) algorithms (Figure 1d and 2d). There was no statistically significant 
difference in relapse rate observed between permissive and non-permissive cases, although 
there is clearly visible separation between groups on the graph pointing smaller relapse rate 
among HLA-DPB1 non-permissive MM group of patients. Logistic regression analysis of 
patient, donor and graft variables which might be associated with relapse incidence was 
performed in regards to HLA-DPB1 level matching, and none of the analysed characteristics 
were found to have a significant influence on the researched endpoint (Table 3). 
4. Discussion 
 
The results of this study pointed out several findings about HLA-DPB1 allele 
distribution, HLA-DPB1 matching rate among patients and their MUDs as well as the role of 
HLA-DPB1 alleles in HSCT. The most frequent HLA-DPB1 alleles found in our study group 
(HLA-DPB1*04:01, -DPB1*04:02P, -DPB1*03:01P, -DPB1*02:01, -DPB1*01:01,) are in 
concordance with the frequencies of HLA-DPB1 alleles in Croatian population [25]. It is 
interesting to note that the most frequent allele among our patients, HLA-DPB1*04:01, is also 
the most frequent allele in the rest of the Europe and North America but its frequency lowers 
as we go towards south. At the same time, the frequency of DPB1*04:02 increases and it is 
the most frequent allele in Middle and South America. In Asia, the frequency of HLA-
DPB1*04:01 is high in the east and as we move to the west its frequency decreases, and the 
frequency of HLA-DPB1*02:01 becomes predominant [26]. Also, an important observation is 
that these four alleles are present in 82.31% of individuals of the researched group. According 
to Sidney et al., a panel of five HLA-DPB1 molecules (DPB1*01:01, DPB1*02:01, 
DPB1*04:01, DPB1*04:02, and DPB1*05:01) is encountered with an average phenotypic 
frequency of >15% across the seven main populations (Australia, Europe, North America, 
Oceania, South America, Southeast Asia, and sub-Saharan Africa) covering ~92% of the 
average population at the HLA-DPB1 locus [27]. 
The frequency of HLA-DPB1 alleles was approximately equal in both donors and 
patients; however, only 7/82 patient/MUD pairs shared a complete HLA-DPB1 compatibility. 
Since none of the transplanted pairs had HLA–DPB1 typing performed before transplantation, 
this was an unexpected finding. However, the low percentage of HLA-DPB1 matched 
patient/MUD pairs is comparable to the rate observed in the IHWS [11], French [12], 
Austrian [13] and Swiss [15] studies. According to our results and data from the above 
mentioned studies, mismatching at the HLA-DPB1 alleles is very frequent in patient/ MUD 
pairs (up to ~91%). The mismatching rate of HLA-DPB1 alleles in HLA identical siblings is 
around 5% [28, 29]. This is a consequence of the low linkage disequilibrium between HLA-
DPB1 and HLA-DR/-DQ loci as well as the high HLA-DPB1 polymorphism and thus the 
probability of finding a 10/10 MUD also matched for HLA-DPB1 alleles is very low. 
Therefore, to overcome the difficulty of finding a HLA-DPB1 MUD, the classification of 
HLA-DPB1 alleles according to their immunogenicity as permissive or non-permissive has a 
benefit for increasing the number of acceptable donors [5, 6]. Tram et al., recently performed 
a study about the likelihood of identifying a HLA-DPB1 permissive MUD for patients with 
10/10 matched donors in the Be The Match Registry and concluded that a young HLA-DPB1 
permissive MUD is at the start possible for 59% of the patients carrying TCE group 3 alleles 
and improves to 70% after additional DPB1 typing of 4 donors [30]. The ability to find a 
HLA-DPB1 permissive match for each TCE group is similar to the frequency of expression of 
these alleles in given populations. 
The data from different studies presented in Table1 mostly suggest that HLA-DPB1 
allele MMs may be tolerated, or are even beneficial in HSCT. Fleischhauer et al., observed in 
their study that being matched or mismatched for HLA-DPB1 alleles according to TCE 
groups provides a better prediction of transplant outcomes than does consideration of HLA-
DPB1 allele level matching alone [14]. Our study supports findings that HLA-DPB1 
mismatching reduces the risk of disease relapse compared with HLA-DPB1 allele-matched 
cases. The same observation was reported in a few other studies [10, 11, 17]. On the other 
hand, the association of HLA-DPB1 MMs with theoretically expected higher GvHD 
occurrence was not proven in this research (no effect on GvHD). The possible explanation of 
the beneficial effect of HLA-DPB1 MMs regarding disease relapse rate is the knowledge that 
the vast majority of leukemic cells expressed variable levels of DPB1 antigens on the cells 
surface and could be killed by DPB1-specific cytotoxic T cells, inducing a graft versus 
leukaemia effect (GvL) [31, 32]. In this way, allospecific T cells, which are responsible for 
GvHD, might also be directly responsible for the anti-leukemic effect with HLA-DPB1 as a 
specific GvL target. Rutten et al., demonstrated that HLA-DP-specific T cells were found in 
patients with beneficial clinical responses in both presence and absence of GvHD and the 
conclusion was that the balance between GvHD and GvL reactivity in each individual is also 
determined with the local environment and the induction of other immune responses [33]. 
In the current study, no significant differences between HLA-DPB1 permissive and 
non-permissive MMs on HSCT outcome were observed and the TCE3-group algorithm 
compared to the TCE4-group algorithm showed similar associations with all investigated 
clinical endpoints. These results are not in agreement with the data reported in three different 
studies [5, 6, 14] with better prediction of HSCT outcome with permissive DPB1 MMs 
compared to non-permissive MMs. These differences are possibly associated with the 
transplant characteristics of each investigated group such as the intensity of the conditioning 
regimen, stem cell source and GvHD prophylaxis. In the mentioned studies, the conditioning 
regimen was mostly MAC while in our study group, around half of the patients (54.87%) 
were treated with RIC using ATG which is known to decrease the risk of GvHD after 
allogeneic HSCT [34], and because of that it maybe influences or even overcomes the HLA-
DPB1 MM effect. On the other hand, the BM was the main stem cell source in those studies 
compared with our study group whereas PBSC were used in the majority of patients (71.95%) 
and it is known that the use of PBSC compared to BM is associated with increased risk of 
GvHD [35]. The multivariate analysis did not point to any of these two factors as significant 
for the HSCT outcome in our group of patients. However, it is possible that those two factors 
in combination with the reactivity of the HLA-DPB1 allospecific T cells influence the balance 
between GvHD and GvL. According to data presented in the study by Fleischhauer et al., 
allogeneic PBSC rejection was mediated by CD4+ T-cells recognizing a HLA-DPB1*09:01 
alloantigen (high immunogenic group 1)  from the patient’s blood [36]. So, it is possible that 
the strength of HLA-DPB1 immunogenicity directs the HSCT outcome toward GvL or toward 
GvHD. In that case, a classification of HLA-DPB1 alleles as permissive or non-permissive 
should be applied in the selection of MUDs to improve HSCT outcome. 
In conclusion, patient/MUD pairs matched for HLA-DPB1 were associated with a 
significantly higher incidence of disease relapse compared to pairs who were permissive or 
non-permissive HLA-DPB1 mismatched. Our study should be helpful in our transplant centre 
practice regarding the impact of HLA-DPB1 matching since it is clear that HLA-DPB1 alleles 
should be treated as transplantation determinant. These results suggest that HLA-DPB1 
matching is not preferable for patient/MUD pairs, but this should be confirmed in a larger and 
more homogeneous patient cohort to help further assess the influence of HLA-DPB1 alleles 
on outcomes after HSCT. 
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Table 1. A literature overview of the HLA-DPB1 allele associations with the unrelated hematopoietic stem cell transplantation outcomes. 
 
Legend: GvHD = graft versus host disease (a=acute; c=chronic); HLA = human leukocyte antigen; MM = mismatch; No =Number; Non-p = 
non-permissive; NRM = non-relapse mortality; OS = overall survival; TRM = transplant relate mortality; / = not investigated in the study 
 
Studie No of patients OS GvHD NRM/TRM RELAPSE 
Petersdorf EW et al. 2001, [8] 205 HLA-DPB1 MM - no effect  Two HLA-DPB1 MM - 
increased risk of GvHD 
/ / 
Loiseau P et al. 2002, [9] 57 Two HLA-DPB1 MM - 
poorer survival 
Two HLA-DPB1 MM - 
increased GvHD 
/ HLA-DPB1 MM - no 
effect  
Zino E et al. 2004, [5] 118 / Non-p HLA-DPB1 MM – 
increased aGvHD  
Non-p HLA-DPB1 MM - 
increased TRM 
Non-p HLA-DPB1 MM – 
no effect 
Shaw BE et al. 2006, [10] 423 HLA-DPB1 match - 
worse OS 
/ / HLA-DPB1 match - 
higher relapse rate 
Shaw BE et al. 2007, [11] 5929 HLA-DPB1 MM – no effect HLA-DPB1 MM -  
increased risk of aGvHD  
HLA-DPB1 MM - higher 
TRM 
HLA-DPB1 MM - 
decreased relapse 
Loiseau P et al. 2007, [12] 334 HLA-DPB1 MM - no effect HLA-DPB1 MM - no effect / HLA-DPB1 MM - no 
effect 
Ludajic K et al. 2008, [13] 161 HLA-DPB1 MM - worse OS HLA-DPB1 MM – 
increased GvHD  
HLA-DPB1 MM - higher 
TRM 
HLA-DPB1 MM - no 
effect 
Crocchiolo R et al. 2009, [6] 621 Non-p HLA-DPB1 MM – 
lower OS  
Non-p HLA-DPB1 MM - 
increased GvHD 
Non-p HLA-DPB1 MM – 
increased NRM  
Non-p HLA-DPB1 MM - 
no effect 
Fleischhauer K et al. 2012, [14] 8539 / Non-p HLA-DPB1 MM - 
increased aGVHD 
Non-p HLA-DPB1 MM – 
increased NRM  
Non-p HLA-DPB1 MM – 
no effect 
Bettens F et al. 2012, [15] 246 HLA-DPB1 match - 
beneficial effect for OS 
HLA-DPB1 MM – 
increased GvHD 
/ / 
Touzeau C et al. 2012, [16] 141 Non-p HLA-DPB1 MM – no 
effect 
Non-p HLA-DPB1 MM – 
no effect 
/ Non-p HLA-DPB1 MM – 
no effect 
Pidala J et al. 2014, [17] 8003 / HLA-DPB1 MM – 
increased GvHD 
HLA-DPB1 MM – 
increased TRM 
HLA-DPB1 MM – 
decreased relapse 
Gagne K et al. 2015, [18] 1342 HLA-DPB1 MM – no effect HLA-DPB1 MM – 
increased GvHD 
HLA-DPB1 MM – no 
effect 
Non-p HLA-DPB1 MM – 
increased relapse 
Moyer AM et al. 2017, [19] 153 HLA-DPB1 MM – no effect HLA-DPB1 MM – 
increased cGvHD; Non-p 
HLA-DPB1 MM - 
increased aGVHD 
HLA-DPB1 MM – no 
effect 
HLA-DPB1 MM – no 
effect 
Table 2. Patients and matched unrelated donors characteristics and hematopoietic stem cell 
transplantation variables. 
 
Patient and donor characteristics n                         % 
Number of patient/MUD pairs 82  
Patients age: year, median (range)           40 (1-62)   
Donor age:  year, median (range)             34 (18-58)   
Gender - patient/donor:    
   Female-female 17 20.73 
   Female-male 11 13.41 
   Male-female 24 29.27 
   Male-male 30 36.59 
Diagnosis:    
   Acute myelogenous leukaemia (AML) 37 45.1 
   Acute lymphoblastic leukaemia (ALL) 17 20.7 
   Myelodysplastic syndrome (MDS) 6 7.3 
   Chronic myelogenous leukaemia (CML) 3 3.7 
   Non-Hodgkin lymphoma (NHL) 4 4.9 
   Hodgkin lymphoma (HL) 3 3.7 
   Myelofibrosis 2 2.4 
   Severe combined immunodeficiency (SCID) 3 3.7 
   Other 7 8.5 
Conditioning regimen:    
   Myeloablative (MAC) 37 45.12 
   Reduced intensity (RIC)  45 54.88 
Stem cell source:    
   Bone marrow (BM) 23 28.05 
   Peripheral blood (PBSC) 59 71.95 
Number of HLA-DPB1 mismatches:   
   0 7 8.53 
   1 50 47.56 
   2 25 43.91 
Legend: HLA = human leukocyte antigen; MUD = matched unrelated donor; n = number;  
 
 
 
 
 
 
 
 
Table 3. The logistic regression analysis of different risk factors associated with overall survival, non-relapse mortality, graft versus host disease 
occurrence and relapse incidence in patients with hematological malignancies who underwent HSCT from unrelated donor (N=82). 
 
Legend: GvHD = graft versus host disease; HLA = human leukocyte antigen; NRM = non-relapse mortality; OS = overall survival; TCE3 = three-group 
T-cell epitope; TCE4 = four-group T-cell epitope 
 
 
 
 
 
 
 OS NRM  GvHD RELAPSE 
Variable Odds ratio P Odds ratio P Odds ratio P Odds ratio P 
Patient characteristics: 
Age  
Gender  
Conditioning regimen  
Graft type 
Diagnosis - myeloid 
Diagnosis - lymphoid 
Patient-donor HLA-DPB1 disparity: 
Number of HLA-DPB1 mismatches 
TCE3 permissive/non permissive disparity 
TCE4 permissive/non permissive disparity 
 
2.04 [0.50-8.29] 
0.52 [0.15-1.73] 
0.71 [0.22-2.27] 
1.23 [0.36-4.20] 
0.69 [0.15-7.43] 
1.02 [0.08- 6.12] 
         
0.29 [0.04-2.55] 
0.58 [0.15-2.23] 
1.68 [0.39-7.21] 
 
0.32 
0.29 
0.58 
0.74 
0.79 
0.62 
 
0.27 
0.43 
0.48 
 
7.99 [0.71-90.04] 
1.45 [0.33-6.37] 
1.36 [0.32-5.80] 
0.67 [0.14-3.07] 
0.58 [0.25-1.93] 
1.37 [0.34-7.70] 
 
3.16 [0.23-41.95] 
1.94 [0.10-36.24] 
1.62 [0.34-7.78] 
 
0.04 
0.62 
0.67 
0.61 
0.24 
0.59 
 
0.38 
0.65 
0.54 
 
1.18 [0.28-5.10] 
2.24 [0.67-7.51] 
1.83 [0.57-5.93] 
1.19 [0.33-4.27] 
2.06 [0.45-7.52] 
0.27 [0.13-2.01] 
 
2.06 [0.28-14.72] 
0.60 [0.16-2.25] 
1.12 [0.26-4.67] 
 
0.81 
0.19 
0.31 
0.78 
0.82 
0.66 
 
0.47 
0.45 
0.88 
 
0.29 [0.05-2.01] 
0.67 [0.17-2.63] 
0.54 [0.13-2.19] 
4.04 [0.76-21.23] 
0.21 [0.14-1.94] 
2.21 [0.79-8.23] 
 
0.26 [0.03-3.67] 
1.07 [0.23-5.72] 
0.66 [0.11-3.72] 
 
0.22 
0.57 
0.40 
0.10 
0.18 
0.23 
 
0.19 
0.92 
0.63 
 
 
 
Legend: HLA = human leukocyte antigen; MM = mismatch  
Figure 1. Association of HLA-DPB1-match and HLA-DPB1 permissive/non-permissive mismatch on HSCT outcomes in patient/matched unrelated donor 
pairs according to three-group T-cell epitope (TCE3) algorithm: A) overall survival; B) non-relapse mortality; C) graft versus host disease; D) relapse rate. 
  
Legend: HLA = human leukocyte antigen; MM = mismatch  
Figure 2. Association of HLA-DPB1-match and HLA-DPB1 permissive/non-permissive mismatch on HSCT outcomes in patient/matched unrelated donor 
pairs according to four-group T-cell epitope (TCE4) algorithm: A) overall survival; B) non-relapse mortality; C) graft versus host disease; D) relapse rate. 
